United States · Bill · HR
H.R. 1730 (117th)
Speeding Therapy Access Today Act of 2021
Introduced
10 March 2021
Last action
10 March 2021 · Introduced
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Bilirakis, Gus M. [R-FL-12], G. K. Butterfield, Darren Soto, ALCEE HASTINGS, Jefferson Van Drew, Mike Levin, John Joyce, Rodney Davis, Rep. Tenney, Claudia [R-NY-24], Rep. Lee, Susie [D-NV-3], Susan Wild, Rep. Fitzpatrick, Brian K. [R-PA-1], Antonio Delgado, Debbie Lesko, Grace Napolitano, Chris Jacobs, Tom Cole, Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Kelly, Mike [R-PA-16], Rep. Ross, Deborah K. [D-NC-2], Rep. Kustoff, David [R-TN-8], Rep. Gottheimer, Josh [D-NJ-5], Jared Huffman, Rep. DeSaulnier, Mark [D-CA-10], Rep. Lynch, Stephen F. [D-MA-8], Dean Phillips, Rep. Neguse, Joe [D-CO-2], Jenniffer González-Colón, John Yarmuth, Rep. Dean, Madeleine [D-PA-4], Sanford Bishop, Cynthia Axne, Eric Swalwell, Rep. Stansbury, Melanie A. [D-NM-1], Tom O'Halleran, Rep. Wilson, Joe [R-SC-2], Rep. Crow, Jason [D-CO-6], J. Hill, Rep. Matsui, Doris O. [D-CA-7], Markwayne Mullin, Don Bacon
Subjects
Healthcare
Source updated
5 December 2025
Summary
Speeding Therapy Access Today Act of 2021 This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases. The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies). The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations. The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
10 March 2021
Referred
Referred to the Subcommittee on Health.
Source: Committee
10 March 2021
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
10 March 2021
Introduced
Introduced in House
Source: IntroReferral
10 March 2021
Introduced
Introduced in House
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
- Introduced in House · 10 March 2021 · Official file
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 10 March 2021
Introduced in House (PDF)
Introduced in House · EN · 10 March 2021
Introduced in House
summary · EN · 10 March 2021
Sponsors
- Rep. Bilirakis, Gus M. [R-FL-12] · R · Sponsor
- G. K. Butterfield · D · Sponsor
- Darren Soto · D · Cosponsor
- ALCEE HASTINGS · D · Cosponsor
- Jefferson Van Drew · R · Cosponsor
- Mike Levin · D · Cosponsor
- John Joyce · R · Cosponsor
- Rodney Davis · R · Cosponsor
- Rep. Tenney, Claudia [R-NY-24] · R · Cosponsor
- Rep. Lee, Susie [D-NV-3] · D · Cosponsor
- Susan Wild · D · Cosponsor
- Rep. Fitzpatrick, Brian K. [R-PA-1] · R · Cosponsor
- Antonio Delgado · D · Cosponsor
- Debbie Lesko · R · Cosponsor
- Grace Napolitano · D · Cosponsor
- Chris Jacobs · R · Cosponsor
- Tom Cole · R · Cosponsor
- Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
- Rep. Kelly, Mike [R-PA-16] · R · Cosponsor
- Rep. Ross, Deborah K. [D-NC-2] · D · Cosponsor
- Rep. Kustoff, David [R-TN-8] · R · Cosponsor
- Rep. Gottheimer, Josh [D-NJ-5] · D · Cosponsor
- Jared Huffman · D · Cosponsor
- Rep. DeSaulnier, Mark [D-CA-10] · D · Cosponsor
- Rep. Lynch, Stephen F. [D-MA-8] · D · Cosponsor
- Dean Phillips · D · Cosponsor
- Rep. Neguse, Joe [D-CO-2] · D · Cosponsor
- Jenniffer González-Colón · R · Cosponsor
- John Yarmuth · D · Cosponsor
- Rep. Dean, Madeleine [D-PA-4] · D · Cosponsor
- Sanford Bishop · D · Cosponsor
- Cynthia Axne · D · Cosponsor
- Eric Swalwell · D · Cosponsor
- Rep. Stansbury, Melanie A. [D-NM-1] · D · Cosponsor
- Tom O'Halleran · D · Cosponsor
- Rep. Wilson, Joe [R-SC-2] · R · Cosponsor
- Rep. Crow, Jason [D-CO-6] · D · Cosponsor
- J. Hill · R · Cosponsor
- Rep. Matsui, Doris O. [D-CA-7] · D · Cosponsor
- Markwayne Mullin · R · Cosponsor
- Don Bacon · R · Cosponsor
- · hsif00 · Standing
Related records
- related to → Speeding Therapy Access Today Act of 2021
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/1730
- Open data entity: https://api.congress.gov/v3/bill/117/hr/1730
- us · 117-hr-1730 · source updated 5 December 2025